CSL Ltd banner

CSL Ltd
ASX:CSL

Watchlist Manager
CSL Ltd Logo
CSL Ltd
ASX:CSL
Watchlist
Price: 139.485 AUD -0.22% Market Closed
Market Cap: AU$67.7B

Relative Value

The Relative Value of one CSL stock under the Base Case scenario is hidden AUD. Compared to the current market price of 139.485 AUD, CSL Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CSL Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

CSL Competitors Multiples
CSL Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
CSL Ltd
ASX:CSL
67.4B AUD 3.1 34.2 11.3 14.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Abbvie Inc
NYSE:ABBV
362.3B USD 5.9 86.6 14.4 20
US
Amgen Inc
NASDAQ:AMGN
188.5B USD 5.1 24.3 14.1 14.1
US
Gilead Sciences Inc
NASDAQ:GILD
170.4B USD 5.8 20.1 12.6 15.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.6B USD 9.5 28.8 21.6 22.6
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.9B USD 5.5 17.4 12.8 14.7
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.8 -66.6 -60.1
NL
argenx SE
XBRU:ARGX
36B EUR 10.1 32.5 35 35.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
40.6B USD 10.9 129.5 72.4 80.5
P/S Multiple
Revenue Growth P/S to Growth
AU
CSL Ltd
ASX:CSL
Average P/S: 3 063 003.6
3.1
4%
0.8
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.9
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5.1
3%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
5.8
5%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.5
11%
0.9
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.5
10%
0.5
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
NL
argenx SE
XBRU:ARGX
10.1
27%
0.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
10.9
34%
0.3
P/E Multiple
Earnings Growth PEG
AU
CSL Ltd
ASX:CSL
Average P/E: 46.7
34.2
10%
3.4
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
86.6
97%
0.9
US
Amgen Inc
NASDAQ:AMGN
24.3
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
20.1
16%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.8
17%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.4
13%
1.3
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
NL
argenx SE
XBRU:ARGX
32.5
32%
1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
129.5
84%
1.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
CSL Ltd
ASX:CSL
Average EV/EBITDA: 24.3
11.3
7%
1.6
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.4
12%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.1
10%
1.4
US
Gilead Sciences Inc
NASDAQ:GILD
12.6
9%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.6
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.8
18%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
NL
argenx SE
XBRU:ARGX
35
50%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
72.4
67%
1.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
CSL Ltd
ASX:CSL
Average EV/EBIT: 27.2
14.2
10%
1.4
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
20
23%
0.9
US
Amgen Inc
NASDAQ:AMGN
14.1
3%
4.7
US
Gilead Sciences Inc
NASDAQ:GILD
15.5
13%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.6
17%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.7
23%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
NL
argenx SE
XBRU:ARGX
35.7
51%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
80.5
69%
1.2
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett